middle.news
How Will Rhythm Biosciences Turn a $2.26M Loss into Commercial Success?
2:32pm on Wednesday 18th of February, 2026 AEDT
•
Healthcare
Read Story
How Will Rhythm Biosciences Turn a $2.26M Loss into Commercial Success?
2:32pm on Wednesday 18th of February, 2026 AEDT
Key Points
Half-year loss of $2.26 million, down from prior profit
ColoSTAT transitions from development to commercial launch with ISO accreditation
NHS England selects ColoSTAT for independent evaluation
GeneType platform expands via strategic partnerships and scientific validation
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Rhythm Biosciences (ASX:RHY)
OPEN ARTICLE